By George Ongkojoyo 
Researchers at the Japan Advanced Institute of Science and Technology (JAIST) have announced a breakthrough in oncology that leverages the unique biological properties of the Japanese tree frog (Dryophytes japonicus). In a study recently published in the journal Gut Microbes, a team led by Associate Professor Eijiro Miyako identified a specific strain of bacteria, Ewingella americana, which displays an unprecedented ability to target and eliminate cancerous tumors in laboratory mice. This research signals a shift in the field of microbial therapy, moving beyond the general modulation of the gut microbiome toward the use of specific, intravenously administered "living drugs" that seek out and destroy malignant cells with surgical precision.
The discovery comes at a time when the medical community is increasingly looking toward the natural world to solve the complexities of treatment-resistant cancers. While immunotherapy and chemotherapy remain the cornerstones of modern oncology, their limitations—including systemic toxicity and the inability to penetrate the dense, oxygen-poor cores of solid tumors—have necessitated the search for alternative delivery mechanisms. The JAIST team’s work suggests that the answer may lie in the complex microbial ecosystems found within the intestines of amphibians and reptiles.
A New Frontier in Microbial Oncology
For decades, the relationship between bacteria and cancer was viewed primarily through the lens of risk, with certain pathogens linked to the development of gastric and cervical malignancies. However, the emerging field of "bactofection" and bacterial-mediated tumor therapy is flipping this narrative. The study conducted at JAIST focused on isolating individual bacterial strains that could survive the journey through the bloodstream and selectively colonize the harsh environment of a tumor.
Unlike previous methodologies that relied on fecal microbiota transplants (FMT) to alter a patient’s overall immune landscape, this new approach treats the bacterium as an active pharmacological agent. By screening the internal flora of indigenous Japanese wildlife, the researchers aimed to find a "specialist" organism—one capable of navigating the mammalian circulatory system without triggering a lethal systemic immune response, yet aggressive enough to dismantle a tumor from the inside out.
The Isolation and Selection Process: From the Wild to the Lab
The research began with a comprehensive survey of the microbiome of three distinct species: the Japanese tree frog (Dryophytes japonicus), the Japanese fire belly newt (Cynops pyrrhogaster), and the Japanese grass lizard (Takydromus tachydromoides). The team collected and cultured 45 different bacterial strains from the intestines of these animals, seeking organisms that could thrive in varied environments.
The screening process was rigorous. Each strain was evaluated for its "anticancer potential," which included its ability to inhibit cancer cell growth in vitro and its safety profile in vivo. Of the 45 strains, nine showed significant promise. However, one specific bacterium, Ewingella americana, isolated from the Japanese tree frog, stood out for its exceptional performance. E. americana is a Gram-negative, facultative anaerobic bacterium. Its status as a "facultative anaerobe" is critical; it means the organism can generate energy through aerobic respiration if oxygen is present but can switch to fermentation or anaerobic respiration in the absence of oxygen.
Unprecedented Results: Achieving a 100% Complete Response Rate
To test the efficacy of E. americana, the JAIST researchers utilized a mouse model of colorectal cancer, a disease often characterized by its resistance to traditional therapies once it reaches advanced stages. The results were described by the team as "remarkable." A single intravenous injection of the bacteria led to a 100% complete response (CR) rate. In every subject treated, the tumors were entirely eliminated.
The study included a comparative analysis against two of the most widely used treatments in modern oncology: immune checkpoint inhibitors (specifically anti-PD-L1 antibodies) and liposomal doxorubicin, a potent chemotherapy agent. While these standard therapies showed some success in slowing tumor growth, they failed to achieve the total eradication observed with the E. americana treatment. The survival rate for the mice treated with the frog-derived bacteria was significantly higher, with no recurrence of the primary tumor observed during the study’s monitoring period.
The Dual-Pronged Biological Assault
The effectiveness of Ewingella americana is attributed to a "dual attack" mechanism that addresses two of the biggest hurdles in cancer treatment: direct cell destruction and immune evasion.
1. Direct Intratumoral Proliferation
Solid tumors are notorious for having "hypoxic zones"—areas with very little oxygen caused by rapid, disorganized growth that outstrips the blood supply. These zones are often unreachable by chemotherapy and are resistant to radiation. Because E. americana is a facultative anaerobe, it finds these hypoxic regions to be an ideal environment. Upon entering the tumor, the bacteria began to multiply at an exponential rate. Researchers found that the bacterial population within the tumor increased by approximately 3,000-fold within the first 24 hours. This massive localized explosion of bacteria causes direct physical and metabolic damage to the surrounding cancer cells.
2. Orchestrating a Systemic Immune Response
Beyond its direct "search and destroy" mission, E. americana acts as a biological beacon. Tumors often employ "cloaking" mechanisms to hide from the host’s immune system. The presence of E. americana strips away this anonymity. The study found that the bacteria’s colonization of the tumor triggered a massive influx of immune cells, including T cells, B cells, and neutrophils. These cells, once alerted to the site, began producing high concentrations of pro-inflammatory signaling molecules known as cytokines, specifically Tumor Necrosis Factor-alpha (TNF-α) and Interferon-gamma (IFN-γ). This localized "cytokine storm" effectively turns the body’s own defenses against the malignancy, ensuring that any cancer cells not killed by the bacteria are destroyed by the immune system.
Precision Targeting: Why Healthy Organs Remain Untouched
One of the primary concerns with using live bacteria as a medical treatment is the risk of sepsis or the colonization of vital organs. However, the JAIST study revealed a high degree of "tumor tropism"—a natural preference for cancerous tissue over healthy tissue.
The researchers identified three primary reasons why E. americana targets tumors specifically:
- The Enhanced Permeability and Retention (EPR) Effect: Tumor blood vessels are "leaky" and disorganized compared to healthy vessels. This allows larger particles, including bacteria, to slip out of the bloodstream and into the tumor mass more easily than they can enter healthy organs.
- The Hypoxic Microenvironment: The lack of oxygen in the center of tumors provides a sanctuary for E. americana, protecting it from the high-oxygen environments of the lungs or heart.
- Immune Privilege: The interior of a tumor is often "immunosuppressed," meaning the body’s normal defenses are dampened there. This allows the bacteria to grow undisturbed within the tumor, whereas they are quickly identified and neutralized if they attempt to colonize healthy, immune-active organs.
Safety Profile and Pharmacokinetics
Safety data from the study were equally encouraging. Following intravenous administration, the bacteria were found to have a half-life in the bloodstream of only 1.2 hours. Within 24 hours, the bacteria were virtually undetectable in the blood, having either been cleared by the liver and kidneys or having successfully nested within the tumor.
Crucially, the researchers conducted detailed autopsies and histological examinations of the mice’s vital organs, including the heart, lungs, liver, spleen, and kidneys. They found no evidence of bacterial colonization in these healthy tissues. While the treatment did cause a brief spike in systemic inflammation—a natural reaction to the introduction of a foreign organism—this returned to baseline levels within 72 hours. A 60-day long-term observation period showed no signs of chronic toxicity, weight loss, or behavioral changes in the treated mice.
The Historical Context of Bacterial Therapy
While the use of frog bacteria is a modern innovation, the concept of using pathogens to fight cancer dates back to the late 19th century. Dr. William Coley, often called the "Father of Immunotherapy," observed that some cancer patients went into remission after developing severe skin infections. He began injecting patients with a mixture of killed bacteria (known as "Coley’s Toxins") to stimulate an immune response.
However, with the advent of radiotherapy and chemotherapy in the mid-20th century, bacterial therapy fell out of favor due to its unpredictability and the lack of genetic engineering tools. The JAIST study represents a modern refinement of Coley’s original observation, utilizing high-resolution screening and a better understanding of the tumor microenvironment to transform a primitive observation into a sophisticated, targeted therapy.
Broader Implications and Future Research
The success of E. americana in treating colorectal cancer in mice opens the door to a wide array of future applications. The JAIST team has already outlined plans to test the therapy against other "hard-to-treat" solid tumors, such as pancreatic cancer, which is notorious for its dense stroma that blocks traditional drugs, as well as triple-negative breast cancer and melanoma.
Future research will focus on several key areas:
- Dose Optimization: Determining the "minimum effective dose" to maximize tumor destruction while minimizing the initial inflammatory response.
- Combination Therapies: Investigating whether E. americana can act as a "sensitizer," making tumors more susceptible to existing chemotherapies or radiation.
- Direct Injection: Exploring whether direct intratumoral injection could be more effective for accessible tumors, such as those found in the breast or skin.
- Human Translation: The transition from mouse models to human clinical trials is the most significant hurdle. Human immune systems are more sensitive to Gram-negative bacteria than mouse immune systems, meaning researchers may need to genetically attenuate the bacteria to ensure human safety without sacrificing efficacy.
Biodiversity as a Medical Resource
The study also serves as a powerful argument for the preservation of global biodiversity. The fact that a potential cure for cancer was found within the gut of a common Japanese tree frog highlights how much of the natural world remains unexplored for its medicinal potential.
"Nature has spent millions of years perfecting biological interactions," the researchers noted in their concluding remarks. "By looking at the microbiomes of diverse species, we can find tools that have already been ‘engineered’ by evolution to survive and interact with complex biological systems in ways we are only beginning to understand."
The research was supported by several prestigious Japanese institutions, including the Japan Society for the Promotion of Science (JSPS) and the Japan Science and Technology Agency (JST). As the team moves toward the next phase of development, the scientific community will be watching closely to see if the humble tree frog has indeed provided the key to a new era of cancer treatment.
